To hear about similar clinical trials, please enter your email below

Trial Title: 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

NCT ID: NCT02174679

Condition: Carcinoid Cancer
Neuroendocrine Tumors
Medullary Thyroid Cancer
Cancers Expressing Somatostatin Receptors

Conditions: Official terms:
Neuroendocrine Tumors

Study type: Expanded Access

Overall status: No longer available

Intervention:

Intervention type: Drug
Intervention name: 68Ga DOTATATE
Description: Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.

Other name: 68Ga DOTATATE PET/CT Scan

Summary: To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Detailed description: This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Older than 18 years the time of radiotracer administration - Provides written informed consent - Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline - Able to remain still for duration of each imaging procedure (about 30 minutes) Exclusion Criteria: - Less than 18 years-old at the time of radiotracer administration - Pregnant or nursing - Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) - Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Locations:

Facility:
Name: UCLA Hospital

Address:
City: Los Angeles
Zip: 90095
Country: United States

Lead sponsor:
Agency: Jonsson Comprehensive Cancer Center
Agency class: Other

Source: Jonsson Comprehensive Cancer Center

Record processing date: ClinicalTrials.gov processed this data on March 01, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT02174679
http://pet.ucla.edu

Login to your account

Did you forget your password?